Finemedix Co., Ltd. (KOSDAQ:387570)
South Korea · Delayed Price · Currency is KRW 6,800.00
+350.00 (5.43%)
At close: Apr 3, 2026
Finemedix Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 9,523 | 9,960 | 10,154 | 8,142 | 7,254 |
Other Revenue | -0 | -0 | -0 | -0 | - |
| 9,523 | 9,960 | 10,154 | 8,142 | 7,254 | |
Revenue Growth (YoY) | -4.39% | -1.91% | 24.71% | 12.25% | -8.30% |
Cost of Revenue | 4,920 | 4,255 | 4,514 | 3,736 | 3,811 |
Gross Profit | 4,603 | 5,705 | 5,640 | 4,406 | 3,443 |
Selling, General & Admin | 6,141 | 4,761 | 3,904 | 4,023 | 4,417 |
Research & Development | 562.4 | 554.53 | 497.78 | 650.75 | 819.38 |
Amortization of Goodwill & Intangibles | 45.61 | 59.4 | 45.97 | 52.11 | 70.68 |
Other Operating Expenses | 169.71 | 149.61 | 135.96 | 149.65 | 164.85 |
Operating Expenses | 7,184 | 5,841 | 4,767 | 5,067 | 5,756 |
Operating Income | -2,580 | -135.69 | 873.58 | -661.25 | -2,313 |
Interest Expense | -93.43 | -116.61 | -198.81 | -255.4 | -239.15 |
Interest & Investment Income | 117.05 | 39.31 | 48.77 | 34.91 | 7.96 |
Earnings From Equity Investments | - | - | - | -200 | - |
Currency Exchange Gain (Loss) | -1.08 | 195.54 | -29.72 | 5.9 | 34.46 |
Other Non Operating Income (Expenses) | 1.14 | -8.41 | 483.89 | 27.5 | 305.59 |
EBT Excluding Unusual Items | -2,557 | -25.86 | 1,178 | -1,048 | -2,204 |
Gain (Loss) on Sale of Investments | - | - | - | - | -6.15 |
Gain (Loss) on Sale of Assets | 4.87 | -180 | - | 1,342 | 10.53 |
Pretax Income | -2,552 | -205.86 | 1,178 | 293.67 | -2,200 |
Income Tax Expense | -673.85 | -181.71 | 1.84 | 54.09 | -657.02 |
Earnings From Continuing Operations | -1,878 | -24.15 | 1,176 | 239.58 | -1,543 |
Minority Interest in Earnings | - | - | - | - | 133.47 |
Net Income | -1,878 | -24.15 | 1,176 | 239.58 | -1,410 |
Net Income to Common | -1,878 | -24.15 | 1,176 | 239.58 | -1,410 |
Net Income Growth | - | - | 390.80% | - | - |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 3 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 3 |
Shares Change (YoY) | 12.35% | 5.42% | 1.75% | 38.53% | 9.53% |
EPS (Basic) | -346.00 | -5.00 | 261.11 | 53.20 | -433.59 |
EPS (Diluted) | -346.00 | -5.00 | 257.00 | 53.00 | -434.00 |
EPS Growth | - | - | 384.91% | - | - |
Free Cash Flow | -3,486 | -424.77 | 1,042 | -2,127 | -875.99 |
Free Cash Flow Per Share | -642.29 | -87.93 | 227.36 | -472.25 | -269.47 |
Gross Margin | 48.34% | 57.28% | 55.55% | 54.12% | 47.46% |
Operating Margin | -27.10% | -1.36% | 8.60% | -8.12% | -31.89% |
Profit Margin | -19.72% | -0.24% | 11.58% | 2.94% | -19.43% |
Free Cash Flow Margin | -36.61% | -4.26% | 10.26% | -26.12% | -12.08% |
EBITDA | -1,619 | 859.96 | 1,838 | 298.38 | -1,330 |
EBITDA Margin | -17.00% | 8.63% | 18.10% | 3.67% | -18.33% |
D&A For EBITDA | 961.79 | 995.65 | 964.01 | 959.62 | 983.4 |
EBIT | -2,580 | -135.69 | 873.58 | -661.25 | -2,313 |
EBIT Margin | -27.10% | -1.36% | 8.60% | -8.12% | -31.89% |
Effective Tax Rate | - | - | 0.16% | 18.42% | - |
Advertising Expenses | 207.18 | 114.74 | 189 | 153.45 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.